{"title":"鞘氨醇-1-磷酸受体亚型1拮抗剂可能是吗啡诱导的痛觉过敏和抗痛觉耐受性的未满足的医学需求","authors":"Y. Brik","doi":"10.3166/dea-2021-0165","DOIUrl":null,"url":null,"abstract":"Opioids such as morphine are frequently used for chronic pain management despite their many adverse effects. Ongoing research aims at either finding new treatments to replace opioids or reducing its heavy adverse effects due to long-term use: opioid-induced hyperalgesia and antinociceptive tolerance. In a recent study, Doyle et al. (2020) demonstrate that the activation of sphingosine-1-phosphate receptor subtype 1 (S1PR1) in the central nervous system contributes to morphine-induced hyperalgesia and antinociceptive tolerance in a rodent model of chronic pain. By targeting S1PR1 with molecules with functional antagonistic properties (some of which are FDA-approved for multiple sclerosis treatment), hyperalgesia and tolerance were significantly reduced without modifying morphine pharmacokinetics or efficacy.","PeriodicalId":11303,"journal":{"name":"Douleur Et Analgesie","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sphingosine-1-phosphate Receptor Subtype 1 Antagonists may be the Unmet Medical Need for Morphine-induced Hyperalgesia and Antinociceptive Tolerance\",\"authors\":\"Y. Brik\",\"doi\":\"10.3166/dea-2021-0165\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Opioids such as morphine are frequently used for chronic pain management despite their many adverse effects. Ongoing research aims at either finding new treatments to replace opioids or reducing its heavy adverse effects due to long-term use: opioid-induced hyperalgesia and antinociceptive tolerance. In a recent study, Doyle et al. (2020) demonstrate that the activation of sphingosine-1-phosphate receptor subtype 1 (S1PR1) in the central nervous system contributes to morphine-induced hyperalgesia and antinociceptive tolerance in a rodent model of chronic pain. By targeting S1PR1 with molecules with functional antagonistic properties (some of which are FDA-approved for multiple sclerosis treatment), hyperalgesia and tolerance were significantly reduced without modifying morphine pharmacokinetics or efficacy.\",\"PeriodicalId\":11303,\"journal\":{\"name\":\"Douleur Et Analgesie\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Douleur Et Analgesie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3166/dea-2021-0165\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Douleur Et Analgesie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3166/dea-2021-0165","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Sphingosine-1-phosphate Receptor Subtype 1 Antagonists may be the Unmet Medical Need for Morphine-induced Hyperalgesia and Antinociceptive Tolerance
Opioids such as morphine are frequently used for chronic pain management despite their many adverse effects. Ongoing research aims at either finding new treatments to replace opioids or reducing its heavy adverse effects due to long-term use: opioid-induced hyperalgesia and antinociceptive tolerance. In a recent study, Doyle et al. (2020) demonstrate that the activation of sphingosine-1-phosphate receptor subtype 1 (S1PR1) in the central nervous system contributes to morphine-induced hyperalgesia and antinociceptive tolerance in a rodent model of chronic pain. By targeting S1PR1 with molecules with functional antagonistic properties (some of which are FDA-approved for multiple sclerosis treatment), hyperalgesia and tolerance were significantly reduced without modifying morphine pharmacokinetics or efficacy.
期刊介绍:
Douleur et Analgésie, première revue internationale francophone consacrée à la douleur, a été créée en 1988. De par la qualité scientifique et l’indépendance de ses publications, ce trimestriel a reçu d’emblée un accueil favorable auprès des chercheurs et cliniciens spécialisés dans le domaine. Á l’occasion de la reprise de la revue en 2006 par les Éditions Springer, le comité éditorial a souhaité s’ouvrir davantage à la francophonie, y compris nord américaine, pour mieux partager les connaissances et renforcer la valeur scientifique de la revue.